Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like Gene-RADAR Authorized For Zika Testing: Interview With Nanobiosym Founder And CEO, April 20, 2017 Bay Area's PellePharm Wins FDA Breakthrough Tag for Genetic Rare Disease Drug November 19, 2017 Kymera Emerges Out of Stealth Mode With $30M and a Top Team of Drug Hunters October 29, 2017